leisure time -WSS

leisure time

author：explore 2025-09-28 02:47:22 - browse：776

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： First Opinion Podcast: How to protect health care in times of war

leisure time

WSS

CDC says it’s too soon to assess risk posed by Covid subvariant

How the drug

Emergency medicine has repudiated 'excited delirium.' Now what?

California store owner shot dead in dispute over displaying Pride flag: Police

Medtronic CEO on promising devices for diabetes, hypertension

The FDA weighs the risks of candy

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

How to make over

Psychedelics group wrestles with new pharma identity

Health officials lay out plans to cope with respiratory virus season

As demand for Covid shots wanes, Moderna seeks its next success

Paying for Covid pills will soon shift to insurers

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Intellia plays down concerns on accidental germline transmission

Medicare proposal to cover medical devices draws a mixed reaction

Eli Lilly to pay $200M for Beam’s stake in gene

leisure time

FDA greenlights medical device to combat bladder issues

Telehealth options flood the market as retailers push virtual care

Readout Newsletter: XBI biotech index, Akero Therapeutics

Medtronic CEO on promising devices for diabetes, hypertension

Senate panel to vote on hospitals, PBMs, prisoner care

California store owner shot dead in dispute over displaying Pride flag: Police

leisure time

hotspot

focus

entertainment